Europe is set to launch its first commercial orbital cancer laboratory, aimed at studying tumors in microgravity conditions to uncover new drug targets. SPARK Microgravity GmbH announced this initiative during a session titled “Curing cancer in space” at the Frontiers Science House in Davos. This facility will operate in low Earth orbit, allowing researchers to conduct experiments that gravity-bound laboratories cannot perform.
The laboratory’s goal is to accelerate the timeline between discovery and therapy by providing insights into biological processes that remain obscured under Earth’s gravitational influence. According to SPARK Microgravity, the unique conditions of microgravity can expose biological signals that are typically masked by gravity’s effects.
Unlocking New Insights in Microgravity
Gravity significantly influences how cells grow, settle, and interact. On Earth, researchers often have to work around these gravitational constraints. In contrast, the microgravity environment of space facilitates a more accurate study of complex cancer behaviors. The orbital lab will enable three-dimensional tumor growth experiments, allowing scientists to model cancers more closely to their behavior within the human body.
Allison Bajet, CEO and co-founder of SPARK Microgravity, likened the difference between Earth and space experiments to listening to a symphony in a noisy environment versus in a soundproof room. She stated, “Simulated microgravity is like trying to listen to a symphony inside a construction zone. The construction noise being the gravity, buoyancy, and sedimentation creates distortions that make it hard to hear the music.”
This enhanced clarity in research could lead to the identification of new drug targets, potentially explaining why certain treatments work in theory but fail in practice.
Collaborative Efforts for Space-Based Research
SPARK Microgravity is not pursuing this project in isolation. The company has formed partnerships with Axiom Space and Voyager Technologies to establish the necessary infrastructure for research operations in low Earth orbit. ATMOS Space Cargo will assist with future missions to return biological samples to Earth for analysis, which is crucial for translating findings into clinical applications.
An initial flight demonstration is scheduled for May 2024, supported by the Swedish Space Corporation. This mission will test systems intended for upcoming cancer experiments. Additionally, SPARK Microgravity plans to collaborate with French startup HyPrSpace, which is developing Baguette-One, a launch vehicle set to become the first rocket launched from France. This partnership strengthens the connection between European launch capabilities and biomedical research.
The announcement at Frontiers Science House placed the orbital lab initiative before a global audience, including policymakers, investors, and industry leaders. The organizers noted that the Davos setting is designed to foster the integration of scientific research into global decision-making.
SPARK Microgravity envisions the orbital lab as a pivotal step toward normalizing space research in the field of drug development. The company believes that microgravity research will become a standard tool in the future, further advancing our understanding of cancer and improving treatment options for patients worldwide.
